(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Oil, energy and food: Which countries in Europe are most exposed to higher food prices? - 2Italy's Beloved Trevi Fountain Hides A Unique Secret That Can Be Explored Underground
- 3NASA's Artemis 2 pilot Victor Glover listens to 'Whitey on the Moon' every Monday. This is why.
- 4The 15 Best Business visionaries Under 40
- 5Journalist reported killed in the Gaza Strip
- Women take pride in Holy Week roles after a Spanish Catholic brotherhood's procession excluded them
- The Way to Monetary Freedom: A Viable Aide
- Excited visitors for NASA's moon launch jockey for prime views
- Research highlights potential dangers of ultra-processed foods for women under 50 regarding precancerous polyps
- Doggie diversity in size and shape began at least 11,000 years ago
- Countdown begins for long-awaited Artemis II moon mission
- Iranian-linked drone attack kills Kurdish couple in northern Iraq
- The most effective method to Beat Dental Tension and Guarantee Customary Exams
- Extraordinary Shows to Long distance race on a Plane
